RÉSUMÉ
Lift-off protocols for thin films for improved extended X-ray absorption fine structure (EXAFS) measurements are presented. Using wet chemical etching of the substrate or the interlayer between the thin film and the substrate, stand-alone high-quality micrometer-thin films are obtained. Protocols for the single-crystalline semiconductors GeSi, InGaAs, InGaP, InP and GaAs, the amorphous semiconductors GaAs, GeSi and InP and the dielectric materials SiO2 and Si3N4 are presented. The removal of the substrate and the ability to stack the thin films yield benefits for EXAFS experiments in transmission as well as in fluorescence mode. Several cases are presented where this improved sample preparation procedure results in higher-quality EXAFS data compared with conventional sample preparation methods. This lift-off procedure can also be advantageous for other experimental techniques (e.g. small-angle X-ray scattering) that benefit from removing undesired contributions from the substrate.
Sujet(s)
Membrane artificielle , Nanoparticules/composition chimique , Semiconducteurs , Manipulation d'échantillons/méthodes , Spectrométrie d'émission X/méthodes , Nanoparticules/ultrastructure , Protéines associées à la pancréatiteRÉSUMÉ
Apart from qualitative flags, that are typically inefficient and uninformative, haematology instruments provide little meaningful information about lymphocyte populations or the lineage of atypical or immature elements, The CELL-DYN Sapphire haematology analyser uses integrated optical and fluorescence (488 nm) measurements, with FL1 (FITC) and FL2 (PE) detectors being configured for fluorescent analysis. As monoclonal antibodies (Mab) are widely used as cellular probes, and are likely to constitute the future basis for immunodifferentials, we explored the feasibility of implementing immunofluorescence on this routine haematology analyser. An extensive series of Mab (CD2, CD3, CD4, CD8, CD11b, CD13, CD14, CD16, CD19, CD22, CD33, CD34, CD41, CD42b, CD45, CD56, CD61, CD64, CD235a and HLA-DR) were tested singly or in FITC/PE combinations. Analyser processing and data acquisition was achieved using CD-Sapphire automated CD61 immunoplatelet or CD3/4/8 assay procedures and, apart from mixing EDTA-blood and antibody, no further sample manipulation was required. Downloaded raw files were processed with cytometry software, and all evaluated reagents showed population discrimination analogous to flow cytometry. Practical procedures were straightforward and required minimal operator training. Extended information that can be obtained from monoclonal antibodies with a routine haematology analyser has the potential to extend haematology laboratory practices and positively impact laboratory and clinical efficiency.
Sujet(s)
Anticorps monoclonaux/analyse , Marqueurs biologiques/analyse , Tests hématologiques/méthodes , Anticorps monoclonaux/immunologie , Marqueurs biologiques/sang , Plaquettes/cytologie , Plaquettes/immunologie , Cellules de la moelle osseuse/composition chimique , Cellules de la moelle osseuse/cytologie , Cellules de la moelle osseuse/immunologie , Érythrocytes/immunologie , Technique d'immunofluorescence/méthodes , Cellules souches hématopoïétiques/immunologie , Immunophénotypage , Tissu lymphoïde/cytologie , Tissu lymphoïde/immunologie , TitrimétrieRÉSUMÉ
BACKGROUND AND OBJECTIVES: The blood platelet content (in numbers) of platelet concentrates is required for production quality control and to predict clinical responses. MATERIALS AND METHODS: This study compared the performance of automated counting from impedance and optical instruments to data from immunoplatelet reference analysis. RESULTS: All methods showed good linearity with evidence of significant instrument-specific deviations from the line of agreement. Relational formulae largely corrected bias, but did not resolve platelet count variability. A second confounding factor, related to the proportion of small (activated) platelets, was also shown to contribute to intermethod discrepancies. CONCLUSIONS: Blood processing centres should establish correction factors for each instrument compared to reference methods, such as the immunoplatelet count.
Sujet(s)
Numération des plaquettes/méthodes , Analyse de variance , Biais (épidémiologie) , Impédance électrique , Humains , Norvège , Optique et photonique , Numération des plaquettes/instrumentation , Numération des plaquettes/normes , Numération des plaquettes/statistiques et données numériques , Transfusion de plaquettes , Contrôle de qualitéRÉSUMÉ
Prophylactic and therapeutic platelet transfusions are increasingly used for patients with conditions associated with thrombocytopenia in order to prevent the development of potentially life threatening bleeding. These clinical strategies have led to a significant expansion in platelet unit manufacture, and this now represents a major resource and cost commitment for blood banks. As part of the manufacturing process, blood banks are required to implement control procedures, and the determination of platelet counts in particular is necessary to confirm that the quality of platelet unit production meets the standards defined by national or international guidelines. Apart from linearity analysis and comparisons of platelet counts given by different instruments, there has been no systematic standardisation of platelet counting methods in blood bank practice because to date there has been no suitable reference method for counting platelets in citrate anticoagulants. The recent introduction of an automated immunoplatelet procedure on the Cell-Dyn CD4000 provides a means of determining a true platelet count that is unaffected by changes induced either by storage or anticoagulant. The CD4000 in its routine configuration also provides simultaneous impedance and optical platelet counts and this study was therefore undertaken in order to compare all three different platelet counting methods in parallel with a representative series of platelet units. Platelet counts determined after sub-sampling of platelet units into EDTA vs plain non-anticoagulated tubes revealed no differences in impedance or immunoplatelet counts but generally lower optical counts when aliquoted into tubes that did not contain EDTA. This study therefore routinely used EDTA for platelet unit sub-samples. Comparative results of platelet counts for buffy coat platelet units (n = 36) aliquoted into EDTA indicated that the impedance count was higher than the reference immunoplatelet count by a mean factor of 1.25 while the optical count was lower by a mean factor of 0.87. The degree of impedance count overestimation was particularly consistent while the optical count underestimation was more variable. Linearity studies of 10 fresh platelet units showed no deviation in the range 0-2305 x 10(9) l(-1) for impedance and 0 to 1420 x 10(9) l(-1) for the optical counts, and the relative numerical relationships between impedance and optical counts were conserved throughout the range of dilutions tested. In the CD4000 optical analysis, blood samples anticoagulated with EDTA showed a distinctive elliptical population distribution that fell within the system thresholds. In contrast, the optical pattern observed for platelet units (in CPD) and ACD-anticoagulated venous blood showed a wider 90 degrees scatter with a population of platelet events above the upper parallel discriminator. As these were excluded from the optical count (but were still identified as platelets by the immunoplatelet method) it meant that the optical counts of samples in citrate-based anticoagulants were systematically lower than immunoplatelet counts. Platelet units (n = 15) analysed daily over a seven day period of storage revealed that the greatest decline in platelet counts was with the optical measurement while the most stable value was obtained by impedance analysis. The results of the immunoplatelet analysis further suggested a progressive increase in small platelets with increasing storage time. The use in this study of a standardised immunoplatelet reference method to examine the question of analyser suitability for determining platelet counts/yields of platelet units thus provided a number of important findings. An impedance platelet counting method is utilised by the great majority of haematology instruments in current use, and in common with the CD4000 analyser, a correction factor is employed to take account of RBC/platelet coincidence. This study found that when analysed samples such as platelet units were RBC-free, that an inappropriate correction factor was applied. Consequently, the CD4000 impedance platelet count will provide reliable platelet counts, irrespective of the day of platelet unit storage, when a factor of 1.25 is applied to the system-reported result. By comparison, optical methods are more likely to be affected by subtle morphological changes that may result from anticoagulants or progressive storage time. The method limitations documented by this study may well affect many other analysers and mean that the implementation of process control statistics related to platelet counts may be less reliable than previously assumed. It is suggested that standardisation could be much better achieved if there was some form of system cross-calibration that was referenced to an independent method such as an immunoplatelet assay. It is proposed that studies of this type should be extended to a wide assessment of platelet count accuracy of blood bank instruments in order to standardise data within national organisations. If consistent inter-instrument correction factors such as those documented here can be identified, it would considerably increase the relevance of determining platelet counts in production control processes.
Sujet(s)
Banques de sang/normes , Numération des plaquettes/normes , Adulte , Anticoagulants/pharmacologie , Antigènes CD/analyse , Automatisation , Plaquettes/composition chimique , Plaquettes/effets des médicaments et des substances chimiques , Conservation de sang , Acide citrique/pharmacologie , Acide édétique/pharmacologie , Impédance électrique , Glucose/analogues et dérivés , Glucose/pharmacologie , Humains , Intégrine bêta3 , Néphélométrie et turbidimétrie , Numération des plaquettes/instrumentation , Glycoprotéines de membrane plaquettaire/analyse , Contrôle de qualité , Normes de référence , Reproductibilité des résultatsRÉSUMÉ
Genetic labeling of tumor cells with the Escherichia coli lacZ reporter gene, encoding the enzyme beta-galactosidase, is widely used for histochemical detection of micrometastases in mice. Recently, we have developed a novel, highly sensitive and specific immunocapture chemiluminescence assay for the quantitation of E. coli beta-galactosidase. This assay achieved a detection limit of 0.01 mU of E. coli beta-galactosidase per milliliter, and 97% signal recovery of purified enzyme added to mouse plasma. LacZ transduced MDA-MB-231 BAG human breast cancer cells grown in vitro released soluble beta-galactosidase into the culture medium, and the concentration found correlated with cell density. Growth of the same cells in nude mice produced readily measurable levels of E. coli beta-galactosidase enzyme activity in host plasma and a highly significant correlation could be demonstrated between the size of primary tumor xenografts and the host plasma level of E. coli beta-galactosidase activity. When mice bearing MDA-MB-231 BAG tumor xenografts were treated intravenously with a single injection of doxorubicin (5 mg/kg), the mean tumor volume after 16 days was reduced 4-fold in the group of doxorubicin-treated mice compared with saline-treated control mice, and the mean level of plasma E. coli beta-galactosidase was correspondingly reduced 3.8-fold in the doxorubicin-treated mice compared with control mice. Sensitive and specific measurement of soluble E. coli beta-galactosidase in blood, using an immunocapture chemiluminescence assay, thus provides objective assessment of tumor burden in mice xenografted with lacZ transduced human tumors. This assay may have important applications as a tool for determining the efficacy of new experimental anti-tumor agents.
Sujet(s)
Escherichia coli/génétique , Techniques de transfert de gènes , Opéron lac , Tumeurs expérimentales/traitement médicamenteux , beta-Galactosidase/sang , Animaux , Escherichia coli/enzymologie , Femelle , Humains , Souris , Souris nude , Transplantation tumorale , Tumeurs expérimentales/enzymologie , Tumeurs expérimentales/anatomopathologie , Transplantation hétérologue , Cellules cancéreuses en culture , beta-Galactosidase/métabolismeRÉSUMÉ
The urokinase plasminogen activator receptor (uPAR) plays a critical role in urokinase-mediated plasminogen activation and thereby in the process leading to invasion and metastasis. Soluble urokinase receptor (suPAR) is released from tumours, and in cancer patients the blood level of soluble receptor is increased. Using an enzyme-linked, immunosorbent assay (ELISA)-specific for the human urokinase receptor, release of soluble receptor was measured in cultures of human breast carcinoma cells, in tumour extracts and in plasma from mice with xenografted human tumours. Soluble human urokinase receptor (shuPAR) was released into culture supernatant during the growth of the human breast cancer cell line MDA-MB-231 BAG, and the level of shuPAR in conditioned medium determined by ELISA was a linear function of both viable cell number and time of incubation. Western blotting showed that the form of shuPAR measured by ELISA in conditioned medium consisted virtually exclusively of the three-domain full-length protein, while uPAR in cell lysates consisted of full-length uPAR as well as the domains (2+3) cleavage product. shuPAR was also released into the plasma of nude mice during growth of MDA-MB-231 BAG, MDA-MB-435 BAG and HCT 116 cells as subcutaneously xenografted tumours. Western blotting demonstrated that the shuPAR released from the xenografted human tumours into plasma consisted of the three-domain full-length protein, despite the finding of some cleaved uPAR in detergent extracts of tumour tissue. The levels of shuPAR determined by ELISA in the plasma of host mice during the growth of xenografted cell lines were highly correlated with tumour volume.
Sujet(s)
Tumeurs du sein/métabolisme , Carcinomes/métabolisme , Activateurs du plasminogène/biosynthèse , Récepteurs de surface cellulaire/biosynthèse , Activateur du plasminogène de type urokinase/biosynthèse , Animaux , Tumeurs du sein/sang , Tumeurs du sein/anatomopathologie , Carcinomes/sang , Carcinomes/anatomopathologie , Test ELISA , Femelle , Humains , Souris , Transplantation tumorale , Activateurs du plasminogène/sang , Récepteurs de surface cellulaire/sang , Récepteurs à l'activateur du plasminogène de type urokinase , Cellules cancéreuses en culture , Activateur du plasminogène de type urokinase/sangSujet(s)
Tumeurs du sein/anatomopathologie , Escherichia coli/génétique , beta-Galactosidase/analyse , Animaux , Escherichia coli/enzymologie , Femelle , Gènes rapporteurs , Humains , Mesures de luminescence , Poumon/cytologie , Poumon/anatomopathologie , Tumeurs du poumon/anatomopathologie , Tumeurs du poumon/secondaire , Souris , Souris nude , Métastase tumorale , Protéines recombinantes/analyse , Protéines recombinantes/génétique , Sensibilité et spécificité , Transfection/méthodes , Transplantation hétérologue , Cellules cancéreuses en culture , beta-Galactosidase/génétiqueRÉSUMÉ
In order to invade and spread cancer cells must degrade extracellular matrix proteins. This degradation is catalysed by the concerted action of several enzymes, including the serine protease plasmin. Several experimental studies have shown that inhibition of plasmin formation reduces cancer cell invasion and metastasis, indicating a critical role of this proteolytic pathway in these processes. In order to further study the role of plasmin in cancer progression, we have characterized urokinase-type plasminogen activator (uPA) mediated plasmin formation in three human breast cancer cell lines. Using monoclonal antibodies against uPA and its receptor uPAR, we have investigated the contribution of uPA and uPAR to invasive capacity in an in vitro invasion assay. MDA-MB-231 BAG cells were found to express high protein levels of uPA, uPAR and PAI-1. MDA-MB 435 BAG cells produced low amounts of uPA, PAI-1 and moderate amounts of uPAR, whereas MCF-7 BAG cells showed low levels of uPA, uPAR and PAI-1 protein. In a plasmin generation assay MDA-MB-231 BAG cells were highly active in mediating plasmin formation, which could be abolished by adding either an anticatalytic monoclonal antibody to uPA (clone 5) or an anti-uPAR monoclonal antibody (clone R3), which blocks binding of uPA to uPAR. The two other cell lines lacked the capacity to mediate plasmin formation. In the Matrigel invasion assay the cells showed activity in this order: MCF-7 BAG < MDA-MB-435 BAG < MDA-MB-231 BAG. Testing MDA-MB-231 BAG cells in the Matrigel invasion assay revealed that invasion could be inhibited in a dose-dependent manner either by the clone 5 uPA antibody or by the clone R3 uPAR antibody, suggesting that the cell surface uPA system is actively involved in this invasive process. It is concluded that these three cell lines constitute a valuable model system for in vitro studies of the role of cell surface uPA in cancer cell invasion and has application in the search for novel compounds which inhibit mechanisms involved in uPA-mediated plasmin generation on cancer cells.
Sujet(s)
Tumeurs du sein/anatomopathologie , Activateur du plasminogène de type urokinase/métabolisme , Anticorps monoclonaux , Sites de fixation , Tumeurs du sein/métabolisme , Réactifs réticulants , Milieux de culture conditionnés , Femelle , Fibrinolysine/biosynthèse , Humains , Invasion tumorale , Fragments peptidiques/immunologie , Fragments peptidiques/métabolisme , Inhibiteur-1 d'activateur du plasminogène/analyse , Récepteurs de surface cellulaire/analyse , Récepteurs de surface cellulaire/métabolisme , Récepteurs à l'activateur du plasminogène de type urokinase , Cellules cancéreuses en culture , Activateur du plasminogène de type urokinase/analyse , Activateur du plasminogène de type urokinase/immunologieRÉSUMÉ
There was good agreement between results obtained with Coulter VCS/Technicon H1 and manual counting with respect to neutrophils and eosinophils. Coulter VCS overestimates the lymphocyte percentage compared to manual counting and to H1. If, however, the percentage of so called "naked" cells are added to the percentage of manually counted lymphocytes, the agreement between VCS and the manual method is improved. The alarms given by the two instruments are of little value in detecting left shift or nucleated red blood cells.
Sujet(s)
Nouveau-né/sang , Numération des leucocytes/instrumentation , Automatisation , Cellules sanguines/ultrastructure , HumainsRÉSUMÉ
A procedure has been developed for the separation and quantitative assay of urinary porphyrins. Urine was directly diluted to a final concentration of 1 MHCl and the amount of porphyrins was determined from the peak-to-trough height deflection of the first derivatives of the absorption spectrum in the region of the Soret band. The ratio uro-/coproporphyrin was determined from the wavelength at which the spectrum intercepted the baseline. The specificity (as shown by a correlation coefficient of 0.99 compared to the method of Doss and Schmidt (1971) Z. Klin. Chem. Klin. Biochem. 9, 415-418), precision (coefficient of variation 5.2 percent) and sensitivity (lower detection limit approx. 0.01 mumol/l) of the present method were highly sufficient to estimate total and different porphyrins in the routine laboratory.